Australia markets open in 6 hours 3 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.07-0.30 (-4.71%)
As of 01:56PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 730.78M
Enterprise value 612.19M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.97
Price/book (mrq)31.69
Enterprise value/revenue 4.48
Enterprise value/EBITDA -6.59

Trading information

Stock price history

Beta (5Y monthly) 3.01
52-week change 3-8.48%
S&P500 52-week change 3-13.66%
52-week high 311.69
52-week low 32.50
50-day moving average 35.41
200-day moving average 35.89

Share statistics

Avg vol (3-month) 31.12M
Avg vol (10-day) 31.59M
Shares outstanding 5124.07M
Implied shares outstanding 6N/A
Float 892.53M
% held by insiders 16.69%
% held by institutions 181.64%
Shares short (30 Aug 2022) 43.42M
Short ratio (30 Aug 2022) 44.22
Short % of float (30 Aug 2022) 43.88%
Short % of shares outstanding (30 Aug 2022) 42.75%
Shares short (prior month 28 July 2022) 43.72M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022


Profit margin -75.48%
Operating margin (ttm)-73.25%

Management effectiveness

Return on assets (ttm)-23.05%
Return on equity (ttm)-166.19%

Income statement

Revenue (ttm)136.66M
Revenue per share (ttm)1.49
Quarterly revenue growth (yoy)-76.90%
Gross profit (ttm)3.04M
Net income avi to common (ttm)-103.14M
Diluted EPS (ttm)-0.94
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)195.8M
Total cash per share (mrq)1.58
Total debt (mrq)77.21M
Total debt/equity (mrq)334.83
Current ratio (mrq)2.35
Book value per share (mrq)0.25

Cash flow statement

Operating cash flow (ttm)-40.46M
Levered free cash flow (ttm)-11.54M